News

Quentis Therapeutics Debuts with $48 Million Series A Financing to Advance First-in-Class Immunotherapies Targeting Endoplasmic Reticulum Stress Response Pathways

–Versant-seeded company focused on applying novel biology to boost anti-tumor immunity– —Foundational science stems from landmark ER stress biology research at Weill Cornell Medicine— —Michael Aberman, M.D., former SVP of Strategy for Regeneron, appointed as President and Chief Executive Officer— NEW YORK–(BUSINESS WIRE)–Quentis Therapeutics Inc., a biotechnology company pursuing next-generation immuno-oncology research and drug development, … Continued

Read More

Machine Learning for Building Personalized Cancer Nanomedicines: Interview with Dr. Daniel Heller

Researchers at the Sloan Kettering Institute and the Weill Cornell Graduate School of Medical Sciences in New York have developed a machine learning approach to design personalized nanoparticle therapies for cancer. Personalized cancer therapies aim to provide a treatment that is tailored to the genetic makeup of a patient’s tumor. They can still cause side effects, however, when they … Continued

Read More

Intravital Imaging Offers View of Cancer Cell Interaction With Immune Response

Far from her native Copenhagen, Denmark, Mikala Egeblad, PhD, works tirelessly to find a means to reduce cancer metastases and recurrences. The significance of her work, now centered in her lab at Cold Spring Harbor Laboratory, Long Island, N.Y., where she is an Associate Professor, has resulted in the Department of Defense Breast Cancer Research … Continued

Read More

New immunotherapy approach boosts body’s ability to destroy cancer cells

Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes after infectious microorganisms. Yet these treatments only benefit some patients, and remain ineffective in the vast majority of cases. … Continued

Read More

Throwing molecular wrench into gene control machine leads to ‘melting away’ of leukemia

PUBLIC RELEASE: 8-JAN-2018 Cold Spring Harbor, NY – Cancer researchers today announced they have developed a way of sidelining one of the most dangerous “bad actors” in leukemia. Their approach depends on throwing a molecular wrench into the gears of an important machine that sets genes into motion, enabling cancer cells to proliferate. In tests in … Continued

Read More

Novel Treatment Causes Cancer to Self-Destruct Without Affecting Healthy Cells

October 9, 2017—BRONX, NY—Scientists at Albert Einstein College of Medicine have discovered the first compound that directly makes cancer cells commit suicide while sparing healthy cells. The new treatment approach, described in today’s issue of Cancer Cell, was directed against acute myeloid leukemia (AML) cells but may also have potential for attacking other types of cancers. “We’re hopeful … Continued

Read More

PRESS RELEASE: The Pershing Square Sohn Cancer Research Alliance Now Accepting Applications for the 2018 Prize for Early-Career Cancer Scientists

NEW YORK, Oct. 2, 2017 /PRNewswire-USNewswire/ — The Pershing Square Sohn Cancer Research Alliance (PSSCRA) today announced the opening of applications for its 2018 Prize for Young Investigators in Cancer Research. The prize of $200,000 per year for up to three years is awarded annually to at least six New York City-based scientists, enabling them to … Continued

Read More

Cancer’s Invasion Equation

We can detect tumors earlier than ever before. Can we predict whether they’re going to be dangerous? We’ve tended to focus on the cancer, but its host tissue—“soil,” rather than “seed”—could help us predict the danger it poses. Over the summer of 2011, the water in Lake Michigan turned crystal clear. Shafts of angled light lit … Continued

Read More

Celgene-backed cancer biotech Repare emerges from stealth with $68M

After 18 months being incubated by Versant Ventures, upstart Repare Therapeutics has emerged from stealth mode with an impressive $68 million, backing from Celgene and some big-name execs. The Montreal and Cambridge, Massachusetts, biotech saw founding investor Versant Ventures co-lead the series A round with MPM Capital. They were also joined by other syndicate investors … Continued

Read More

Ackman Commits New Funds for Cancer Research on Vaccines, Drugs

Read More